GRI
Price
$1.99
Change
+$0.02 (+1.02%)
Updated
Jul 25 closing price
Capitalization
4.97M
HNSBF
Price
$2.74
Change
-$0.26 (-8.67%)
Updated
Jul 17 closing price
Capitalization
233.17M
Interact to see
Advertisement

GRI vs HNSBF

Header iconGRI vs HNSBF Comparison
Open Charts GRI vs HNSBFBanner chart's image
GRI Bio
Price$1.99
Change+$0.02 (+1.02%)
Volume$104.26K
Capitalization4.97M
Hansa Medical AB
Price$2.74
Change-$0.26 (-8.67%)
Volume$7.12K
Capitalization233.17M
GRI vs HNSBF Comparison Chart in %
Loading...
GRI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HNSBF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GRI vs. HNSBF commentary
Jul 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GRI is a StrongBuy and HNSBF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 27, 2025
Stock price -- (GRI: $1.99 vs. HNSBF: $2.74)
Brand notoriety: GRI and HNSBF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GRI: 47% vs. HNSBF: 465%
Market capitalization -- GRI: $4.97M vs. HNSBF: $233.17M
GRI [@Biotechnology] is valued at $4.97M. HNSBF’s [@Biotechnology] market capitalization is $233.17M. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GRI’s FA Score shows that 2 FA rating(s) are green whileHNSBF’s FA Score has 0 green FA rating(s).

  • GRI’s FA Score: 2 green, 3 red.
  • HNSBF’s FA Score: 0 green, 5 red.
According to our system of comparison, GRI is a better buy in the long-term than HNSBF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GRI’s TA Score shows that 5 TA indicator(s) are bullish while HNSBF’s TA Score has 1 bullish TA indicator(s).

  • GRI’s TA Score: 5 bullish, 4 bearish.
  • HNSBF’s TA Score: 1 bullish, 4 bearish.
According to our system of comparison, GRI is a better buy in the short-term than HNSBF.

Price Growth

GRI (@Biotechnology) experienced а +9.34% price change this week, while HNSBF (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.62%. For the same industry, the average monthly price growth was +17.39%, and the average quarterly price growth was +28.36%.

Reported Earning Dates

GRI is expected to report earnings on May 15, 2025.

Industries' Descriptions

@Biotechnology (+7.62% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
HNSBF($233M) has a higher market cap than GRI($4.97M). HNSBF YTD gains are higher at: -8.667 vs. GRI (-85.869). GRI has higher annual earnings (EBITDA): -9.39M vs. HNSBF (-523.23M). HNSBF has more cash in the bank: 250M vs. GRI (3.28M). GRI has less debt than HNSBF: GRI (108K) vs HNSBF (1.02B). HNSBF has higher revenues than GRI: HNSBF (182M) vs GRI (0).
GRIHNSBFGRI / HNSBF
Capitalization4.97M233M2%
EBITDA-9.39M-523.23M2%
Gain YTD-85.869-8.667991%
P/E Ratio0.05N/A-
Revenue0182M-
Total Cash3.28M250M1%
Total Debt108K1.02B0%
FUNDAMENTALS RATINGS
GRI vs HNSBF: Fundamental Ratings
GRI
HNSBF
OUTLOOK RATING
1..100
493
VALUATION
overvalued / fair valued / undervalued
1..100
1
Undervalued
69
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
6181
P/E GROWTH RATING
1..100
2100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GRI's Valuation (1) in the null industry is significantly better than the same rating for HNSBF (69). This means that GRI’s stock grew significantly faster than HNSBF’s over the last 12 months.

GRI's Profit vs Risk Rating (100) in the null industry is in the same range as HNSBF (100). This means that GRI’s stock grew similarly to HNSBF’s over the last 12 months.

GRI's SMR Rating (100) in the null industry is in the same range as HNSBF (100). This means that GRI’s stock grew similarly to HNSBF’s over the last 12 months.

GRI's Price Growth Rating (61) in the null industry is in the same range as HNSBF (81). This means that GRI’s stock grew similarly to HNSBF’s over the last 12 months.

GRI's P/E Growth Rating (2) in the null industry is significantly better than the same rating for HNSBF (100). This means that GRI’s stock grew significantly faster than HNSBF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GRIHNSBF
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
29%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
N/A
Momentum
ODDS (%)
Bullish Trend 3 days ago
90%
Bearish Trend 3 days ago
29%
MACD
ODDS (%)
N/A
Bearish Trend 3 days ago
42%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
86%
Bullish Trend 3 days ago
11%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
85%
Bearish Trend 3 days ago
25%
Advances
ODDS (%)
Bullish Trend 6 days ago
88%
N/A
Declines
ODDS (%)
Bearish Trend 10 days ago
90%
N/A
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
N/A
Aroon
ODDS (%)
Bullish Trend 3 days ago
82%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
GRI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HNSBF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MDBH4.440.37
+9.09%
MDB Capital Holdings LLC
BIGC5.170.13
+2.58%
BigCommerce Holdings
PRGS50.810.84
+1.69%
Progress Software Corp
QLGN2.90N/A
N/A
Qualigen Therapeutics Inc
STN110.20-0.72
-0.65%
Stantec

GRI and

Correlation & Price change

A.I.dvisor indicates that over the last year, GRI has been loosely correlated with IDYA. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if GRI jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GRI
1D Price
Change %
GRI100%
+1.02%
IDYA - GRI
54%
Loosely correlated
-1.33%
SNSE - GRI
40%
Loosely correlated
-2.51%
NLSP - GRI
38%
Loosely correlated
-8.33%
INAB - GRI
37%
Loosely correlated
+1.24%
GOVX - GRI
37%
Loosely correlated
-2.77%
More

HNSBF and

Correlation & Price change

A.I.dvisor indicates that over the last year, HNSBF has been loosely correlated with ENSC. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if HNSBF jumps, then ENSC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HNSBF
1D Price
Change %
HNSBF100%
N/A
ENSC - HNSBF
33%
Loosely correlated
+1.82%
CVAC - HNSBF
33%
Poorly correlated
+0.37%
MLLCF - HNSBF
27%
Poorly correlated
N/A
GNPX - HNSBF
25%
Poorly correlated
-4.59%
GRI - HNSBF
25%
Poorly correlated
+1.02%
More